Latest hyperphosphatemia Stories
-- Data Published Online in the Journal of the American Society of Nephrology -- FREMONT, Calif., Nov. 17, 2014 /PRNewswire/ -- Ardelyx, Inc.
-- Primary endpoint was met for 50 mg twice daily dosing -- FREMONT, Calif., Oct. 1, 2014 /PRNewswire/ -- Ardelyx, Inc.
Nephrologists Seem More Confident That an Iron-Based Phosphate Binder Will Impact the Use of IV Iron vs.
Interest in GCS-100, Velcalcetide, ST-10, GSK-1278863A and Rayaldee Ranges from Moderate to High, According to Findings from Decision Resources Group BURLINGTON, Mass., July 10, 2014 /PRNewswire/
Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage
Marketing Approval Triggers Milestone Payment to Keryx NEW YORK, Jan. 17, 2014 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.
Approval of This Novel Phosphate Binder Will Be a Major Milestone for the Company Cary, NC (PRWEB) September 10, 2013 BioLink Life Sciences, Inc., a
- A volcanic mudflow.